The appointment of Dr. Collins, with his expertise in epilepsy and drug development, is likely to positively impact Bright Minds Biosciences by strengthening their leadership team and enhancing their focus on CNS disorder treatments. This strategic move could lead to advancements in their drug pipeline, potentially increasing investor confidence and positively affecting the stock price.